Coeptis Therapeutics' announcement to pursue DVX201 for treating respiratory viral infections could potentially open new markets and applications for its stem cell therapy platform. This strategic direction not only diversifies its product portfolio but also positions the company in the growing antiviral treatment market. Given the ongoing need for effective treatments against respiratory viruses, this move is likely to be viewed positively by investors and could lead to increased investor interest and potential stock price appreciation in the short term.